Welcome to the international HTA database

Showing [16861 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2021	Malaysian Health Technology Assessment (MaHTAS)	Driving simulator in healthcare
2021	NIHR Health Technology Assessment programme	Intratumoural immune signature to identify patients with primary colorectal cancer who do not require follow-up after resection: an observational study
2021	NIHR Health Technology Assessment programme	Prognostic models of survival in patients with advanced incurable cancer: the PiPS2 observational study
2021	NIHR Health Technology Assessment programme	Feasibility of a RCT of techniques for managing an impacted fetal head during emergency caesarean section: the MIDAS scoping study
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Cabozantinib (reassessment after the deadline: thyroid carcinoma)]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Brentuximab Vedotin (reassessment after the deadline: systemic anaplastic large cell lymphoma; first-line; combination with Cyclophosphamide, Doxorubicin, and Prednisone)]
2021	NIHR Health Technology Assessment programme	Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation
2021	Malaysian Health Technology Assessment (MaHTAS)	Delirium unit in geriatric ward
2021	NIHR Health Technology Assessment programme	Fall prevention interventions in primary care to reduce fractures and falls in people aged 70 years and over: the PreFIT three-arm cluster RCT
2021	Malaysian Health Technology Assessment (MaHTAS)	Digital assisted oral & cranio-maxillofacial surgery
2021	Malaysian Health Technology Assessment (MaHTAS)	Platelet rich plasma (PRP), platelet-rich fibrin (PRF) and concentrated growth factor (CGF) for treatment of periodontal disease
2021	Norwegian Institute of Public Health (NIPH)	Hydrogel rectal spacer SpaceOAR in prostate cancer radiation therapy - health economic evaluation
2021	NIHR Health Technology Assessment programme	Venous access devices for the delivery of long-term chemotherapy: the CAVA three-arm RCT
2021	Norwegian Institute of Public Health (NIPH)	Transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement (SAVR) for patients with severe aortic stenosis and low surgical risk and across surgical risk groups: a health technology assessment
2021	Malaysian Health Technology Assessment (MaHTAS)	Proton beam therapy for the treatment of cancer - an update
2021	National Institute for Health and Care Excellence (NICE)	Onasemnogene abeparvovec for treating spinal muscular atrophy. NICE highly specialised technologies guidance 15
2021	Scottish Health Technologies Group (SHTG)	Minuteful Kidney for home testing of albumin-to-creatine ratio (ACR)
2021	NIHR Health Technology Assessment programme	Long limb compared with standard limb Roux-en-Y gastric bypass for type 2 diabetes and obesity: the LONG LIMB RCT
2021	Scottish Health Technologies Group (SHTG)	Chest wall bracing for children and young people with pectus carinatum
2021	Agency for Healthcare Research and Quality (AHRQ)	Automated-entry patient-generated health data for chronic conditions: the evidence on health outcomes
2021	Agency for Healthcare Research and Quality (AHRQ)	Breast reconstruction after mastectomy
2021	Agency for Healthcare Research and Quality (AHRQ)	Care coordination and care plans for transitions across care settings
2021	Agency for Healthcare Research and Quality (AHRQ)	Cervical ripening in the outpatient setting
2021	National Institute for Health and Care Excellence (NICE)	Givosiran for treating acute hepatic porphyria. NICE highly specialised technologies guidance 16
2021	National Institute for Health and Care Excellence (NICE)	Metreleptin for treating lipodystrophy. NICE highly specialised technologies guidance 14
2021	Health Information and Quality Authority (HIQA)	Systematic review of cost-effectiveness – management of chronic obstructive pulmonary disease in adults
2021	Austrian Institute for Health Technology Assessment (AIHTA)	The economic and societal dimension of parental mental illness. Part 1: systematic review. Part II: economic evaluation framework
2021	Health Information and Quality Authority (HIQA)	Budget impact analysis – management of chronic obstructive pulmonary disease in adults
2021	Austrian Institute for Health Technology Assessment (AIHTA)	≥ 12 month follow-up of patients with spinal muscular atrophy (SMA) treated with Spinraza®, Zolgensma® or combination therapies
2021	Agency for Healthcare Research and Quality (AHRQ)	Disparities and barriers to pediatric cancer survivorship care
2021	NIHR Health Technology Assessment programme	POSNOC-POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: a randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes
2021	Health Information and Quality Authority (HIQA)	Budget impact analysis – National Clinical Guideline. Unexpected intraoperative life threatening haemorrhage guideline
2021	Health Information and Quality Authority (HIQA)	Budget impact analysis – stop smoking
2021	NIHR Health Technology Assessment programme	Primary trabeculectomy versus primary glaucoma eye drops for newly diagnosed advanced glaucoma: TAGS RCT
2021	Malaysian Health Technology Assessment (MaHTAS)	Rezūm therapy for management of benign prostatic hyperplasia
2021	NIHR Health Technology Assessment programme	Sacral nerve stimulation versus the magnetic sphincter augmentation device for adult faecal incontinence: the SaFaRI RCT
2021	Agency for Care Effectiveness (ACE)	MRI-US fusion targeted biopsy for diagnosis of prostate cancer
2021	Malaysian Health Technology Assessment (MaHTAS)	5-aminolevulinic acid (5-ALA) for brain tumour surgical procedure
2021	Agency for Care Effectiveness (ACE)	Transcatheter mitral valve leaflet repair for patients with mitral regurgitation
2021	Malaysian Health Technology Assessment (MaHTAS)	Single dose rifampicin (SDR) as a prophylaxis for leprosy contacts
2021	Agency for Care Effectiveness (ACE)	Transcatheter aortic valve implantation (TAVI) for patients with symptomatic severe native aortic stenosis
2021	Malaysian Health Technology Assessment (MaHTAS)	Versajet hydrosurgery system for wound debridement: an update
2021	Agency for Care Effectiveness (ACE)	Photodynamic therapy for treating non-melanoma skin tumours
2021	Agency for Care Effectiveness (ACE)	Cochlear implants for treating adults with single-sided deafness (SSD)
2021	Institute of Health Economics (IHE)	Long COVID and vulnerable populations
2021	Agency for Care Effectiveness (ACE)	Antibacterial envelope for the prevention of cardiac implantable electronic device-related infections
2021	Agency for Healthcare Research and Quality (AHRQ)	Integrated and comprehensive pain management programs: effectiveness and harms
2021	Agency for Care Effectiveness (ACE)	Repetitive transcranial magnetic stimulation for adults with treatment resistant major depressive disorder
2021	Agency for Healthcare Research and Quality (AHRQ)	Integrating palliative care in ambulatory care of noncancer serious chronic illness: a mixed-methods review
2021	NIHR Health Technology Assessment programme	Cognitive–behavioural therapy for a variety of conditions: an overview of systematic reviews and panoramic meta-analysis
2021	NIHR Health Technology Assessment programme	Patch augmentation surgery for rotator cuff repair: the PARCS mixed-methods feasibility study
2021	Agency for Healthcare Research and Quality (AHRQ)	Interventional treatments for acute and chronic pain: systematic review
2021	NIHR Health Services and Delivery Research programme	Respite care and short breaks for young adults aged 18–40 with complex health-care needs: mixed-methods systematic review and conceptual framework development
2021	Norwegian Institute of Public Health (NIPH)	Surgery for carpal tunnel syndrome: a health technology assessment
2021	National Institute for Health and Care Excellence (NICE)	Endo-SPONGE for treating low rectal anastomotic leak. NICE medical technologies guidance 63
2021	NIHR Health Technology Assessment programme	Universal late pregnancy ultrasound screening to predict adverse outcomes in nulliparous women: a systematic review and cost-effectiveness analysis
2021	Agency for Care Effectiveness (ACE)	Golimumab for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis
2021	Agency for Healthcare Research and Quality (AHRQ)	Interventions to decrease hospital length of stay
2021	National Institute for Health and Care Excellence (NICE)	ClearGuard HD antimicrobial barrier caps for preventing haemodialysis catheter-related bloodstream infections. NICE medical technologies guidance 62
2021	National Institute for Health and Care Excellence (NICE)	Synergo for non-muscle-invasive bladder cancer. NICE medical technologies guidance 61
2021	National Institute for Health and Care Excellence (NICE)	DyeVert Systems for reducing the risk of acute kidney injury in coronary and peripheral angiography. NICE medical technologies guidance 60
2021	National Institute for Health and Care Excellence (NICE)	Plus Sutures for preventing surgical site infection. NICE medical technologies guidance 59
2021	Agency for Healthcare Research and Quality (AHRQ)	Malnutrition in hospitalized adults
2021	NIHR Health Technology Assessment programme	Assistive technology and telecare to maintain independent living at home for people with dementia: the ATTILA RCT
2021	Agency for Healthcare Research and Quality (AHRQ)	Management of high-need, high-cost patients: a "best fit" framework synthesis, realist review, and systematic review
2021	National Institute for Health and Care Excellence (NICE)	UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia. NICE medical technologies guidance 58
2021	National Institute for Health and Care Excellence (NICE)	Danis stent for acute oesophageal variceal bleeding. NICE medical technologies guidance 57
2021	NIHR Health Technology Assessment programme	UK Cohort study to Investigate the prevention of Parastomal Hernia (CIPHER)
2021	National Institute for Health and Care Excellence (NICE)	Alpha-Stim AID for anxiety disorders. NICE medical technologies guidance 56
2021	National Institute for Health and Care Excellence (NICE)	Leukomed Sorbact for preventing surgical site infection. NICE medical technologies guidance 55
2021	National Institute for Health and Care Excellence (NICE)	The VAC Veraflo Therapy system for acute infected or chronic wounds that are failing to heal. NICE medical technologies guidance 54
2021	Belgian Health Care Knowledge Centre (KCE)	Do innovative medicines against cancer always have a real added value?
2021	National Institute for Health and Care Excellence (NICE)	The PLASMA system for transurethral resection and haemostasis of the prostate. NICE medical technologies guidance 53
2021	Agency for Healthcare Research and Quality (AHRQ)	Maternal, fetal, and child outcomes of mental health treatments in women: a systematic review of perinatal pharmacologic interventions
2021	NIHR Health Technology Assessment programme	Prognostic tools for identification of high risk in people with Crohn’s disease: systematic review and cost-effectiveness study
2021	NIHR Health Technology Assessment programme	Thoracoscopic surgical ablation versus catheter ablation as first-line treatment for long-standing persistent atrial fibrillation: the CASA-AF RCT
2021	Scottish Medicines Consortium (SMC)	Afamelanotide (Scenesse) for prevention of photoxicity in adult patients with erythropoietic protoporphyria (EPP)
2021	Scottish Medicines Consortium (SMC)	Upadacitinib for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs)
2021	NIHR Health Technology Assessment programme	Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study
2021	Scottish Medicines Consortium (SMC)	Ravulizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH): in patients with haemolysis with clinical symptom(s) indicative of high disease activity; in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months
2021	NIHR Health Technology Assessment programme	Facilitating the return to work of NHS staff with common mental health disorders: a feasibility study
2021	Scottish Medicines Consortium (SMC)	Ozanimod for adult patients with relapsing remitting multiple sclerosis
2021	NIHR Health Technology Assessment programme	A prognostic model, including quantitative fetal fibronectin, to predict preterm labour: the QUIDS meta-analysis and prospective cohort study
2021	Scottish Medicines Consortium (SMC)	Entrectinib as monotherapy for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion: who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity; and who have not received a prior NTRK inhibitor; who have no satisfactory treatment options
2021	NIHR Health Technology Assessment programme	Palliative radiotherapy combined with stent insertion to reduce recurrent dysphagia in oesophageal cancer patients: the ROCS RCT
2021	NIHR Health Technology Assessment programme	Co-trimoxazole to reduce mortality, transplant, or unplanned hospitalisation in people with moderate to very severe idiopathic pulmonary fibrosis: the EME-TIPAC RCT
2021	Scottish Medicines Consortium (SMC)	Onasemnogene abeparvovec treatment of patients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA type 1, or patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene
2021	Agency for Healthcare Research and Quality (AHRQ)	Physical activity and the health of wheelchair users: a systematic review in multiple sclerosis, cerebral palsy, and spinal cord injury
2021	Scottish Health Technologies Group (SHTG)	NHSScotland COPD Support Service: remote and self-management of high-risk patients with COPD using a web app and machine learning predictive modelling
2021	Agency for Healthcare Research and Quality (AHRQ)	Prehabilitation and rehabilitation for major joint replacement
2021	Agency for Healthcare Research and Quality (AHRQ)	Prehospital airway management
2021	Agency for Healthcare Research and Quality (AHRQ)	Radiation therapy for brain metastases
2021	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Lipoedema – diagnosis, treatment, and experiences]
2021	NIHR Public Health Research (PHR) programme	School-based interventions to prevent anxiety, depression and conduct disorder in children and young people: a systematic review and network meta-analysis
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Opioid pain assessment
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Effectiveness of intra-operative antimicrobial irrigation to prevent surgical site infection in clean surgeries
2021	Agency for Healthcare Research and Quality (AHRQ)	Safety of vaccines used for routine immunization in the United States: an update
2021	NIHR Health Technology Assessment programme	The Arabin pessary to prevent preterm birth in women with a twin pregnancy and a short cervix: the STOPPIT 2 RCT
2021	NIHR Public Health Research (PHR) programme	A school-based, peer-led programme to increase physical activity among 13- to 14-year-old adolescents: the GoActive cluster RCT
2021	Agency for Care Effectiveness (ACE)	Rituximab for treating non-Hodgkin's lymphoma and chronic lymphocytic leukaemia